Teresa Bluhmki

Boehringer Ingelheim (Germany)

Papers

1

Total Citations

66

H-Index

1

About

Dr. Teresa Bluhmki is a leading figure in respiratory drug discovery, specializing in advanced in vitro models for airway research. Her major contribution lies in pioneering the miniaturization of human small airway epithelial models, most notably through her highly cited 2020 work on a 96-Transwell air-liquid interface system (66 citations). This innovation directly addresses the critical challenge of limited cell availability from clinical samples by enabling high-throughput, physiologically relevant testing of respiratory therapies. By scaling down traditional culture formats, Dr. Bluhmki has empowered researchers to conduct more efficient drug screening and toxicology studies with greater reproducibility. Her work has significantly advanced the field’s ability to model human airway biology ex vivo, bridging the gap between preclinical research and clinical application. Through this achievement, she has established herself as a key innovator in developing tools that accelerate the discovery of treatments for respiratory diseases, making her research indispensable for scientists seeking to translate basic biology into therapeutic solutions.

Research Focus

Key Achievements

1
H-Index
1
Papers
66
Total Citations
66
Avg Citations/Paper
🏆 Most Cited Paper
Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model
66 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Boehringer Ingelheim (Germany)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago